Summary.-Sera from 16 of 20 patients with AML at some stage of the disease inhibited the in vitro PHA transformation of normal lymphocytes assessed by measuring the rate of DNA synthesis after 67-70 hours; 42% of pretreatment sera were inhibitory. Inhibitory activity was overcome at PHA concentrations 2-3 times greater than the concentration which allowed maximum discrimination between NHS and leukaemia sera.
Summary.-Sera from 16 of 20 patients with AML at some stage of the disease inhibited the in vitro PHA transformation of normal lymphocytes assessed by measuring the rate of DNA synthesis after 67-70 hours; 42% of pretreatment sera were inhibitory. Inhibitory activity was overcome at PHA concentrations 2-3 times greater than the concentration which allowed maximum discrimination between NHS and leukaemia sera.
PHA transformation of washed lymphocytes obtained from AML patients before treatment and when receiving induction or consolidation (cytoreductive) chemotherapy was reduced only when cultures contained a high proportion of primitive cells. Even in primitive cell contaminated cultures significant responses to PHA could be measured if conditions were modified to prevent increasing acidity.
Reports of reduced in vitro immunological reactions in pretreatment and poor prognosis patients may therefore be due to the presence of primitive cells in culture, and in treated patients to the failure of chemotherapy to reduce the circulating primitive cell count. Serum inhibitory factors may have a significant immunosuppressive effect in vivo, but the accurate assessment of the role of immune mechanisms in AML should attempt the measurement of specific immunity.
THE importance of a failure of immune mechanisms in the aetiology of human leukaemia is unknown and will depend primarily upon the identification of antigens specific for human leukaemia (Harris, 1973) . Autologous acute leukaemia blast cells have been shown to stimulate the in vitro transformation of remission lymphocytes (Viza et al., 1969; Fridman and Kourilsky, 1969) probably because they possessed " new " antigens. Therefore the study of lymphocyte dependent immune reactions in acute leukaemia is justified.
The in vitro lymphocyte response to phytohaemagglutinin (PHA), regarded as a test of " T " cell mediated immunity (Doenhoff et al., 1971) , is superficially easy to measure and accordingly has been wi(lely applied in leukaemia as in many other disorders. Previous studies have indicated that lymphocytes of patients with acute lymphoblastic leukaemia (ALL) before treatment (Astaldi et al., 1966) , when receiving intensive treatment (Bardare et al., 1969) and in remission (Jones et al., 1971) have normal PHA responses. In contrast, in patients with acute myeloid leukaemia (AML) before treatment, Hersh et al. (1971) found that a low PHA response which did not become normal after intensive chemotnerapy was associated with a failure to achieve remission, whereas patients with normal pre-and posttreatment responses achieved remission. These results, together with the results of other in vivo and in vitro tests of lymphocyte reactivity, suggested that patients who failed to recover immune competence (luring treatment had a poor prognosis. However, the in vitro PHA test is open to considerable technical variation-the dose of PHA used must be carefully determined from normal lymphocyte dose-response curves (Fitzgerald, 197 1) and in some studies, as indicated by Jones et al. (1971) 
Leukaeinia patients and treatment
A total of 20 patients with AMI, were studied. Patients on induction chemotherapy received cytosine arabinoside (2-0 mg/kg body weight) daily for 5 days by intravenous injection and daunorubicin (1.5 mg/kg) intravenously on the first day only, followed by 5 days without chemotherapy, this period being prolonged if the bone marrow showed marked hypoplasia. Coulson and Chalmers (1967) , in which plasmagel (Laboratoire Roger Bellon) (3 ml/10 ml blood) was used to sediment red blood cells. After counting morphologically small lymphocytes, the cells were sedimented by centrifugation (350 g, 10 min) and washed once with TC199 culture medium (Welleome) to remove autologous plasma. Sterile, disposable plastic bottles (Sterilin) were used for lymphocyte preparation.
(b) Culture conditions.-(i) For the estimation of lymphocyte reactivity to PHA (Difco PHA-P control 551099) the cell pellet was resuspended in TC199 and normal human serum (0.4 ml NHS/ml TC199) with 0 5-0-7 x 106 lymphocytes in 1-4 ml of medium. Suspensions were usually contaminated with 10-20 times this number of red blood cells and a smaller number (< 105) of polymorphonuclear leucocytes. To 1-4 ml of cell suspension in glass culture tubes (Pyrex 72 x 10 mm) was added 0-6 ml of TC199 medium, with or without a known amount of PHA (usual final concentration in cultures= 7-2 ,tg/ml).
(ii) For the estimation of serum inhibitory activity, washed cells obtained from a healthy donor were suspended in TC199 so that 1 ml aliquots contained 0-3-0-5 x 106 lymphocytes. One ml aliquots of cell suspension were rapidly transferred to culture tubes containing 0-4 ml of serum (leukaemic or NHS, previously stored at -20°C and thawed only once) and then 0-6 ml of TC199 medium with or without PHA (final concentration 7-2 ,tg and 21-6 ,ug/ml of culture) was added. PHA concentration of 7-2 ,ug/ml.
Estimation of DNA synthesis
The method used was similar to that described by Craig, Garrett and Jackson (1969) . Briefly, 041 ml of [1251] 5-iodo 2'deoxyuridine solution (0.021 mg/ml, 20 ,uc/ml at Day 0) was added to each culture tube and after mixing, cultures were incubated for a further one hour at 37TC. Culture tubes were then centrifuged (350 g, 10 min), the supernatant discarded and the cells washed once with 2 ml of Hank's balanced salt solution (HBSS) and resedimented. Cell pellets were stored at -20°C until required. After thawing, 1 ml of bovine serum (4 mg/ml) was added, followed by 1-5 ml of cold 10% (wAr/v) trichloracetic acid and the precipitate was dispersed and sedimented (850 g, 10 miii). The sediment Nwas washed once wsith 2 ml of cold 500 (wA/v) trichloracetic acid and resedimented. y emission of the pellets was assayed with a Wallac Autogamma Counter (GTL 300) at a detection efficiency of 38%.
The optimum concentration of 5-iodo 2'deoxyuridine to be added to cultures was determined in control experiments in which concentrations below 1 05 x 10-4 mg/culture were rate limiting, whilst at 2-1 x 10-4 mg/culture 5-iodo 2'deoxyuridine was in excess without being inhibitory. The rate of 1251 uptake measured after one hour in these conditions continued for a further 2-3 h-ours.
of 10 x 106 per culture. Higher lymphocyte concentrations were inhibitory.
In the analyses log10 of PHA (7.2,ug/ml culture) response was assumed to be normally distributed.
RESULTS
Inhibitory Sera in AML The mean PHA dose ( Fig. 1) Table I .
Of 92 sera obtained from 20 patients at various stages of treatment 36 (390o) were found to be inhibitory (Table Ia) . Of 64 sera collected from 7 patients in remission only 6 (10%), all from the patient (AR) receiving immunotherapy, were inhibitory. In all cases the inhibitory effect of the leukaemia sera was reduced or abolished at the hiaher PHA concentration. Inhibition in sera from patient AR due to HL-A antibodies was also abolished at higher PHA concentrations (21.6 /,g/ml culture).
Four leukaemia sera (not containing detectable HL-A antibodies) which strongly inhibited the PHA response were also tested in the 2-way mixed lymphocyte culture with a final concentration in the culture medium of 2000. The 125IUdR uptakes measured in a 3-hour incubation period after 6 days culture were 30%0, 41%0 48% and 62% of the uptakes with similar cultures containing 20% NHS. The PHA (7a2 pg/ml culture) reactivity of washed lymiphocytes from AML patients Before treatment most AML patients had circulating blastoid or other primitive cells and therefore lymphocyte cultures of these patients were almost always contaminated with primitive cells, making comparison with normal lymphocyte cultures difficult. However, the circulating (Fig. 3) . The differences between the means of the log1o induction responses (4.3677) and the log1o consolidation responses (4.8214) were significant (P 0.05).
The effect of the presence of primitive cells on the in vitro PHA (7.2 ag/ml culture) response With cultures of lymphocytes obtained from AML patients before treatment there was an inverse relationship between the number of primitive cells (usually myeloblasts) present and the PHA response. When the circulating primitive cell concentration was > 8000/mm3 (>ap-proximately 5 x 106 primitive cells/0.5 x 106 lymphocytes/culture), the PHA responses were more than 2 standard deviations below the normal mean value and in many cases were not significantly greater than values obtained in control cultures without PHA. However, when circulating primitive cell concentrations were low (< 8000/mm3 and < approxi- (Table  III) . In the loose capped and medium change AML cultures the control responses (no PHA added) were greater than those measured in sealed tubes. The pH remained in the range 7-2-7-4 in loose capped cultures and was restored to this pH range in cultures with medium change at 24 and 48 hours, but in contrast the pH consistently fell below 7 1 in sealed tube cultures. Significantly, no response occurred in sealed tube cultures whilst a response to PHA could be measured in both types of culture with modified conditions.
In cultures containing normal lymphocytes the PHA responses in sealed tube and medium change cultures were similar (pH in the culture period in the range 7X1-7X3) whereas in loose capped cultures the PHA response was markedly reduced and the pH increased to 7-9-8 1.
DISCUSSION
Sera from the majority of patients with AML inhibited the in vitro response to PHA of both autologous lymphocytes and allogeneic normal lymphocytes. This occurred only in the appropriate culture conditions and especially during the acute phase or in relapse. Similarly, mixed lymphocyte reactions were inhibited by some of the same AML sera, further suggesting that in vivo immune responses could be impaired by factors present in these sera. These observations may explain the reduced delayed hypersensitivity responses in AML which have been reported by some workers (Hersh et al., 1971; Dupuy et al., 1971) .
Inhibitors of the lymphocyte response to PHA occur in sera from patients with a wide variety of clinical conditions including uraemia (Silk, ] 967a), cancer (Silk, 1967b ), Hodgkin's disease (Trubovitz, Masek and Del Rosario, 1966) , idiopathic steatorrhoea (Winter et al., 1967) , syphilis (Levene et al., 1969) , multiple sclerosis and cirrhosis (Knowles et al., 1968) , ataxia telangiectasia (McFarlin and Oppenheim, 1969) , advanced alcoholic cirrhosis (Hsu and Leevy, 1971) , and also in normal foetal plasma (Ayoub and Kasakura, 1971) , normal pregnancy sera (Walker, Freeman and Harris, 1972) and normal sera containing HL-A antibodies (Ceppellini, 1971) . Normal serum itself, when present in cultures at high concentrations, is inhibitory (Cooperband et al., 1967) . Thus, many different inhibitory factors may be involved both specific, for example HL-A antibodies, but probably mostly nonspecific. In one example an a globulin fraction separated and concentrated from NHS was found to be immunosuppressive when added to mitogen stimulated and mixed leucocyte cultures (Cooperband et al., 1969 These studies show that the inhibitory effect of leukaemia serum and the apparent inhibition due to changes in culture conditions when large numbers of blastoid cells are present must be considered when in vitro lymphocyte reactivity in AML is measured.
In vivo it may be important to distinguish between intrinsic cellular defects and the effect of circulating inhibitory factors. The absence in most cases of inhibitory factors during remission might indicate normal " T " lymphocyte reactivity in these patients, whilst the prompt induction of HL-A alloantibodies in a patient receiving immunotherapy indicates that at least some aspects of " B" cell function were effective in this patient during remission.
Disturbance of the proportions of various lymphocyte classes and the presence of inhibitors, whether specific immunoglobulins or nonspecific and heterogeneous, may be secondary concomitants of leukaemia and chemotherapy which interfere with a specific immunological response. Thus, cellular immunosuppressive activity might prove to be of importance in the maintenance and progress of the disease.
Studies are now in progress which will relate the clinical response of patients with AML to the results of these immunological tests and will be reported elsewhere.
